Comparative Pharmacology
Head-to-head clinical analysis: COMPAZINE versus PROMETHAZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COMPAZINE versus PROMETHAZINE HYDROCHLORIDE.
COMPAZINE vs PROMETHAZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dopamine D2 receptor antagonist in the chemoreceptor trigger zone; also blocks alpha-1 adrenergic, histamine H1, and muscarinic M1 receptors.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, blocking the effects of histamine at H1 receptors. It also has anticholinergic, antiemetic, sedative, and antidopaminergic properties.
5-10 mg IM/IV every 3-4 hours as needed; or 25 mg PO/PR twice daily for severe nausea/vomiting.
25-50 mg intramuscular or intravenous injection every 4-6 hours as needed; also 12.5-25 mg orally every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 23 hours (range 15-30 hours) after oral or intramuscular administration. Clinical context: requires multiple daily dosing for steady state.
Terminal elimination half-life is 10-19 hours in adults; prolonged in hepatic impairment (up to 30+ hours) and in elderly.
Renal (approximately 70% as metabolites, <1% unchanged), biliary/fecal (approximately 30%).
Primarily hepatic metabolism; renal excretion of metabolites accounts for <1% of unchanged drug; biliary/fecal excretion of metabolites ~70-80%.
Category C
Category A/B
Antipsychotic (Phenothiazine) / Antiemetic
Antihistamine / Antiemetic